15 results about "Hsv infection" patented technology

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

This invention belongs to the field of natural and chemical medicine technology, and discloses two types of *Symplocos edulis* (a type of plant) from the genus *Symplocos*. Bag Philippians The resorcinol compounds were isolated from [the organism]. The structures of the resorcinol compounds are shown in formula (I) or formula (II). The resorcinol compounds of this invention exhibit significant inhibitory effects on respiratory syncytial virus (RSV) and herpes simplex virus (HSV) even at low concentrations, and show low cytotoxicity and high selectivity, demonstrating promising applications in antiviral drugs and medications for treating diseases caused by RSV and HSV infections.

This invention relates to an HSV-2 nanoparticle vaccine, its preparation method, and its application. The nanoparticles comprise HSV-2 PreF gB mutant protein and ferritin. After assembly, multiple PreF gB mutant proteins are concentrated and displayed on the surface, forming ferritin-PreF gB nanoparticles. The mutation of PreF gB enhances the stability and effective immunogenicity of the gB protein, and its display on the nanoparticle surface further enhances immunogenicity, effectively stimulating the body's cellular immune mechanism, thus becoming an effective vaccine for preventing HSV infection.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

The present disclosure provides, in part, tricyclic compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

This application discloses the application of the IL-37b gene in the preparation of drugs for the prevention and treatment of diseases caused by HSV infection. In animal model experiments, overexpression of the IL-37bΔ1-45 gene significantly prevented HSK relapse and alleviated corneal function in relapsed mouse models, reduced corneal tissue inflammation and infiltration, reduced corneal stromal fibrosis, and significantly decreased viral load in mouse tears, suggesting that IL-37bΔ1-45 may be a promising new method for preventing HSK relapse and has broad application prospects.

The present disclosure provides, in part, azetidine compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.

Disclosed herein are compositions comprising (a) a nucleoside modified polyribonucleotide encoding a herpes simplex virus-2 (HSV-2) glycoprotein E (gE) antigen or an immunogenic fragment thereof, (b) a nucleoside modified polyribonucleotide encoding a HSV-2 glycoprotein I (gI) antigen or an immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for treating HSV infection using the compositions.

Described is a vaccine for use in actively immunising a subject against an infectious disease or a malignant disease, said vaccine comprising: (a) an antibody against an antigen correlated with said infectious disease or malignant disease; or (b) an Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen correlated with said infectious disease or malignant disease, wherein said Fc part is capable of binding a receptor present on or in an antigen presenting cell (APC) selected from the group consisting of Type I: activatory FcγRI, FcγRIIa, FcγRIIc, FcγRIIIa, FcγRIIIb, and inhibitory FcγRIIb; and Type II: neonatal FcR (FcRn) and cytosolic TRIM21. Moreover, described is a vaccine for use in actively immunising a subject against an HSV-associated disease; and (a) wherein said antibody is an anti-HSV antibody and said subject suffers from an acute HSV-associated disease, preferably an acute HSV infection; or (b) wherein in said Fc-containing fusion protein comprising an Fc part of an antibody fused to an antigen, the antigen correlates with an HSV-associated disease.

This invention provides methods of treating, suppressing, inhibiting, reducing an incidence, reducing the pathogenesis of, ameliorating the symptoms of, or ameliorating the secondary symptoms of a primary or recurring Herpes Simplex Virus (HSV) infection, or prolonging the latency to a relapse of an HSV infection, and disorders and symptoms associated with same in a subject comprising the step of contacting the subject with a composition comprising a quindoline (or similar) structure having significant anti-HSV activity.

The present invention pertains to the fields of antibody technology, medicine, pharmacology, infection biology, and medical diagnostics. More specifically, the present disclosure provides a VHH antibody that neutralizes herpes simplex viruses HSV-1 and HSV-2 by blocking the pre-fusion state of the gB fusion protein, as well as methods for using this VHH against HSV infections.

This invention relates to an HSV-1 nanoparticle vaccine, its preparation method, and its application. The nanoparticles comprise HSV-1 PreF gB mutant protein and ferritin. After assembly, multiple PreF gB mutant proteins are concentrated and displayed on the surface, forming ferritin-PreF gB nanoparticles. The mutation of PreF gB enhances the stability and effective immunogenicity of the gB protein, and its display on the nanoparticle surface further enhances immunogenicity, effectively stimulating the body's cellular immune mechanism, thus becoming an effective vaccine for preventing HSV infection.

The present disclosure provides, in part, azetidine compounds, and pharmaceutical compositions thereof, and methods of the treatment and prophylaxis of HSV infections.